论文部分内容阅读
目的观察螺内酯联合厄贝沙坦治疗早期糖尿病肾病微量清蛋白尿的临床疗效。方法 100例早期糖尿病肾病患者,随机分为观察组和对照组,各50例,观察组采用厄贝沙坦联合螺内酯进行治疗;对照组采用厄贝沙坦治疗,连续治疗6个月。比较两组患者治疗效果。结果治疗6个月后,两组患者的尿白蛋白排泄率(UAER)明显降低,且观察组优于对照组,差异有统计学意义(P<0.05)。其余指标比较差异无统计学意义(P>0.05)。结论螺内酯联合厄贝沙坦改善早期糖尿病肾病患者微量清蛋白尿有显著的效果,具有临床价值。
Objective To observe the clinical efficacy of spironolactone combined with irbesartan in the treatment of early stage diabetic nephropathy. Methods 100 patients with early diabetic nephropathy were randomly divided into observation group and control group, 50 cases each. The observation group was treated with irbesartan and spironolactone. The control group was treated with irbesartan for 6 months. Compare the treatment effect of two groups of patients. Results After 6 months of treatment, the urinary albumin excretion rate (UAER) was significantly lower in both groups, and the observation group was superior to the control group, the difference was statistically significant (P <0.05). The remaining indicators were no significant difference (P> 0.05). Conclusion Spironolactone combined with irbesartan in patients with early stage of diabetic nephropathy in patients with microalbuminuria have a significant effect, with clinical value.